Fresenius Kabi USA, LLC 2026-07-29 Health serious FDA
Health · FDA · Recall #FDA-D-0727-2026
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL),… Recall
Issued July 29, 2026 · Fresenius Kabi USA, LLC
In July 2026, Fresenius Kabi USA, LLC recalled the Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL),…, a serious health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Dana Whitfield, RecallCheckr
What this means for you
Presence of Particulate Matter: Hair was found in products
What you should do
- 1 Stop using Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL),… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Fresenius Kabi USA, LLC to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Fresenius Kabi USA, LLC
- Category
- Health
- Recall date
- July 29, 2026
- Units affected
- Not reported
- Sold at
- Nationwide within in the USA
- Recall number
- FDA-D-0727-2026
- Made in
- United States
- Issuing agency
- FDA
In context
- Fresenius Kabi USA, LLC has 18 recalls in our database, including 6 rated Critical.
- We're tracking 3,707 Health recalls in our database.
- This is the 487th Health recall we've logged in 2026.